



## PAX-8 (Klon MRQ-50)

- nukleäre Färbung
- *Maus Monoklonal*
- Ursprungsmarker Niere, weibl. Genitaltrakt (Müller-Epithel) Schilddrüse
- Hochsensitiver Nierenzell Ca-Marker
- Unterscheidung Ovarial-Ca\* von Mamma-Ca
- Unterscheidung Ovarial-Ca\* von Mesotheliom (Calretinin+)
- Unterscheidung Schilddrüsen-Ca (papillär/follikulär) von Lungen-Ca

\* Ausnahme: muzinöse Tumoren; PAX-8-positive Tumoren

### Bestell-Information PAX-8, Klon MRQ-50 (Maus)

#### verfügbare Größen:

0,1 ml konzentriert

0,5 ml konzentriert

1,0 ml konzentriert

1,0 ml gebrauchsfertig

7,0 ml gebrauchsfertig

5 Positivkontrollschnitte

#### Kat.-Nr.

363M-14

363M-15

363M-16

363M-17

363M-18

363S

Tel. 04103/8006-111

**IVD CE**

## Referenzen:

1. Ozcan A *et al.* PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. *Mod Pathol* 2011;24:751-764.
2. Tong GX *et al.* Pax8: a marker for carcinoma of Müllerian origin in serous effusions. *Diagn Cytopathol* 2011;39:567-574.
3. Wiseman W *et al.* Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Müllerian carcinoma in effusions. *Diagn Cytopathol* 2011;39:651-656.
4. Knoepp SM *et al.* Utility of PAX8 and PAX2 immunohistochemistry in the identification of renal cell carcinoma in diagnostic cytology. *Diagn Cytopathol* 2012;40:667-672.
5. Tacha D *et al.* Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. *Appl Immunohistochem Mol Morphol* 2011;19:293-299.
6. Carney EM *et al.* PAX2(-)/PAX8(-)/inhibin A(+) immunoprofile in hemangioblastoma: A helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system. *Am J Surg Pathol* 2011;35:262-267.
7. Haynes CM *et al.* PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens. *Cancer Cytopathol* 2011;119:193-201.
8. Sangoi AR *et al.* PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. *Mod Pathol* 2011;24:412-424.
9. Sangoi AR *et al.* The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10. *Adv Anat Pathol* 2010; 17:377-393.
10. Schmitt AC *et al.* Paired box gene 8, HBME-1, and cytokeratin 19 expression in preoperative fine-needle aspiration of papillary thyroid carcinoma: diagnostic utility. *Cancer Cytopathol* 2010; 118:196-202.
11. McKnight R *et al.* Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma. *Cancer Cytopathol* 2010;118:298-302.
12. Fujiwara M *et al.* PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases. *J Cutan Pathol* 2010;37:938-943.
13. Albadine R *et al.* PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. *Am J Surg Pathol* 2010;34:965-969.
14. Long KB *et al.* PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. *Am J Surg Pathol* 2010;34:723-729.
15. Laury AR *et al.* PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. *Am J Surg Pathol* 2010; 34:627-635.
16. Tong GX *et al.* Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. *Mod Pathol* 2009;22:1218-1827.
17. Jadallah S *et al.* PAX8 expression in clear cell, papillary and chromophobe RCC and urothelial carcinoma of renal pelvis. *Mod Pathol* 2009;22:174A.
18. Netto GJ *et al.* PAX8(+)/p63(-) immunostaining, pattern in renal collecting duct carcinoma (CDC): a helpful immunoprofile in the differential diagnosis of CDC vs urothelial carcinoma of upper urinary tract. *Mod Pathol* 2009;22:186A-187A.
19. Nonaka D *et al.* Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. *Am J Surg Pathol* 2008;32:1566-1571.
20. Tong GX *et al.* Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis? *Am J Surg Pathol* 2008;32:1380-1387.
21. Nonaka D *et al.* Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. *Mod Pathol* 2008;21: 192-200.
22. Bowen NJ *et al.* Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. *Gynecol Oncol* 2007;104:331-337.